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Abstract
Background: Uracil DNA glycosylase (UDG) plays a major role in repair of uracil formed due to
deamination of cytosine. UDG in human cells is present in both the nucleus and mitochondrial
compartments. Although, UDG's role in the nucleus is well established its role in mitochondria is
less clear.
Results: In order to identify UDG's role in the mitochondria we expressed UGI (uracil glycosylase
inhibitor) a natural inhibitor of UDG in the mitochondria. Our studies suggest that inhibition of
UDG by UGI in the mitochondria does not lead to either spontaneous or induced mutations in
mtDNA. Our studies also suggest that UGI expression has no affect on cellular growth or
cytochrome c-oxidase activity.
Conclusions: These results suggest that human cell mitochondria contain alternatives glycosylase
(s) that may function as back up DNA repair protein (s) that repair uracil in the mitochondria.
Introduction
Mitochondrion plays an important role in various cellular
functions ranging from synthesis of lipids to maintenance
of ion homeostasis [1,2]. However, the singular function
that defines this organelle is the production of energy by
the electron transport chain. Mitochondrion is also a sig-
nificant source of reactive oxygen species (ROS), known
to be a potent DNA damaging agent [3]. The integrity of
the mitochondrial genome is essential for effective cellu-
lar processes. The mitochondrion has various active and
passive safe guard strategies to deal with the damaging
effects of ROS on the mitochondrial DNA (mtDNA), one
of them being the repair of the lesions caused by the ROS
production [3]. Mitochondrial repair is not well studied.
It is interesting to note that mtDNA experience more DNA
damage than nuclear DNA [5]. Unlike the nuclear DNA
that does not replicate in terminally differentiated cells
mtDNA is continuously replicated in cells that have
undergone differentiation. Hence lesions in the mtDNA
can prove to be more deleterious [6]. Earlier it was
believed that the mitochondria lack DNA repair mecha-
nisms as thymidine dimers were not repaired in the
mtDNA [4]. However, recent evidence indicates that DNA
repair mechanism do function in the mitochondria
[7,8,25,26]. Various enzymes that are involved in nuclear
DNA repair have isoforms that are targeted to the mito-
chondria [9,10]. Whether these enzymes function in an
identical fashion in the repair of both the nuclear and the
mtDNA is not clear.
The uracil DNA glycosylase (UDG) removes misincorpo-
rated uracil or deaminated cytosine from DNA. Human
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UDG gene encodes two alternative spliced isoforms,
UNG1 and UNG2 [11-13]. Of these the UNG1 is translo-
cated to the mitochondria [14,15]. UNG2 localizes to the
nucleus [15]. Although UNG2's role in repairing nuclear
DNA is well established, the role for mitochondrial UNG1
is not well studied. In this paper we inactivated mitochon-
drial UNG1 by expressing a natural uracil DNA glycosy-
lase inhibitor (UGI) from PBS2 phage that binds to the
active site of UDG in equimolar ratio and inhibits the
UDG enzyme [16]. UGI has been successfully used as a
tool to examine the role of nuclear UNG2 in base excision
repair of misincorporated uracil or deaminated cytosine
in the nuclear DNA [17,18]. In order to elucidate the role
of UDG in in vivo mtDNA repair we targeted UGI to the
mitochondria to inhibit UDG activity. Our studies suggest
that mitochondrial inhibition of UDG is not mutagenic.
This study indicates that alternative DNA glycosylase(s)
may be operative in the mitochondria that might repair
uracil in the mitochondrial genome.
Materials and Methods
Constructs
The reading frame of uracil DNA glycosylase (UDG) that
codes for functional UDG was amplified by PCR using
forward primers (5'CCAGTGCCGCGCGCCAAGATCCAT-
TCGTTGTTTGGAGAGAGCTGGAAGAAG) specific to
human uracil DNA glycosylase that had a BssH II site at
the 5' end and the reverse primers 5'TTGA TCTCGAGT-
CACAGCTCCTTCCAGTCAATGGG that had the Xho I site
engineered at the 5' end. The template used for the ampli-
fication was pTUNG∆84 [13]. The PCR fragment was
cloned into pCMV/myc/mito (Invitrogen) treated with
BssH II and Xho I. The vector has a mitochondial targeting
signal of the subunit VIII of human cytochrome c oxidase
that facilitates targeting of the cloned protein to the mito-
chondria. The construct was named as pCMV UNG.
The complete reading frame of uracil DNA glycosylase
inhibitor gene was amplified using pTZUgi (a gift from
Dr. Umesh Varshney) as a template with forward primers
(5'CCAGTGCCGCGCGCCAAGATCC ATTCGTTGAT-
GACAAA TTTATCTG ACATC) specific to uracil DNA glyc-
osylase inhibitor from phage PBS2 that had a BssH II site
at the 5' end and the reverse primer(5'CGCCCGTTT-
GATCTCGAGTTATAAC ATTTTAATCCATTAC) which had
the Xho I site engineered at the 5' end. The PCR fragment
was cloned into pCMV/myc/mito (Invitrogen). The con-
struct was named as pCMV UGI.
Transfections
Stable transfectants of the above constructs were made in
immortalized normal breast epithelial MCF 12A cells
using lipofectin as a transfecting agent. Briefly, MCF12A
cells were plated to 70 % confluency in a 35 mm dish and
transfected with 2 ug of pCMV UNG and pCMV Ugi. The
cells were selected using G418 as a selection medium. The
clones were selected after plating the cells in a 96 well
plate to single cell dilution and the clones were screened
for integration using PCR. A pCMV/myc/mito/GFP that
has a GFP protein fused to the mitochondrial signal was
used as a control to assay the efficiency of transfection and
the expression of the protein using the vector. An empty
vector was stably transfected and used as a control in all
the experiments.
PCR Screening of clones for stable integration of the 
constructs
Each construct was assayed for stable integration after
transfection using PCR. The primers were the same that
were used for amplifying the gene for cloning namely
UDG specific primers, forward primer: 5'CCAGTGC
CGCGCGCCAAGATCCATTC GTTGTTTGGAGAGAGCT-
GGAAGAAG reverse primer 5'TTGATCTCGAGTCAC
AGCTCCTTCCAGTCAATGGG, for screening UDG stable
integrants and UGI specific primers, forward primer
5'CCAGTGCCGCGCGCCAAGATCCATTCGTTGATGACA
AATTTATCTGACATC and reverse primer 5'CGCCCGTTT-
GATCTCGAGTTATAAC ATTTTAATCCATTAC for screen-
ing Ugi stable integrants. Briefly, the each clone was
transferred from the 96 well plate to a 24 well plate and
DNA was extracted when the wells were confluent using
standard methods. 100 ng of the DNA was used to PCR
amplify the DNA that was transfected. Clones that showed
an intact gene were selected for further analysis.
Isolation of mitochondria
Stable clones and parental MCF12A cells were grown in
T75 flask to seventy percent confluency. The cells were
washed with 1X PBS and treated with 1.5 ml of 0.04%
Digitonin solution (0.4 mg Digitonin /ml,2.5 mM
EDTA,250 mM mannitol, 17 mM MOPS., pH 7.4). The
cells were thoroughly resuspended and homogenized
using ten strokes of a dounce homogenizer on ice. One ml
of 2.5 X sucrose mannitol buffer (525 mM Mannitol, 175
mM Sucrose, 12.5 mM tris-HCl., pH 7.49) was added and
homogenized further using 20 strokes of the homoge-
nizer. Ten micro liter of the homogenate was visualized
under the microscope to assess complete breakdown of
the cells. The mitochondria were isolated by differential
centrifugation [19]. The homogenate was centrifuged at
2500 rpm at 4°C to pellet the nuclei and the supernatant
was further centrifuged at 2500 rpm till no pellet was vis-
ually observed. The supernatant was finally centrifuged at
14000 rpm at 4°C to pellet the mitochondria.
Western Blotting
Stable transfectants were assayed for production of the
UDG protein in the mitochondria by western blotting.
Twenty micrograms of the mitochondrial protein was
electrophoresd on a 12% SDS polyacrylamide gel andMolecular Cancer 2004, 3:32 http://www.molecular-cancer.com/content/3/1/32
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transferred on a nitrocellulose membrane. The membrane
was blocked overnight in a blocking solution containing
5% non-fat milk and probed with the primary antibody
(1:1000 dilution) against UDG (a gift from Dr. Hans
Krokan, Norway). The membrane was washed twice with
TBST and probed with a secondary antibody linked to
horseradish peroxidase. The bands were visualized using
ECL (Amersham Pharmacia) kit. The membrane was then
probed for the house keeper protein beta actin to assess
for equal loading.
RT-PCR
RNA from Ugi stably transfected MCF 12A cells was
extracted using TRIZOL reagent following the manufac-
turers instruction. One and a half micrograms of total
RNA was used for reverse transcription using Superscript
II Rnase H-reverse transcriptase (Invitrogen). Two microli-
tres of the reverse transcribed products was used in the
subsequent PCR reactions. Twenty-five microlitres of the
PCR reactions contained 20 mM Tris-HCL, pH 8.4, 50
mM KCl, 1.5 mM MgCl2, 200 µM dNTP and 10 picomoles
of each primer (forward primer:
5'CCAGTGCCGCGCGCCAAGATCCATTCGTTGAT-
GACAAATTTATCTGACATC and reverse primer
5'CGCCCG TTTGATCTCGAGT TATAACATTTTAATCCAT-
TAC and one unit of Taq DNA polymerase (Invitrogen).
The PCR profile consisted of an initial denaturation at
94°C for 5 minutes and 32 cycles of denaturation at 94°C
for 45 sec, annealing at 58°C for 1 min and extension for
2 min at 72°C with a final extension at 72°C for 10 min.
The PCR products were electrophoresed on a 1% agarose
gel stained with ethidium bromide (0.5 µg/ml) and visu-
alized under UV.
Flow Cytometric Analysis
Proliferation assay was done using a flourescent lipophilic
molecule, 5-(and-6)-carboxyfluorescein diacetate succin-
imidyl ester (CFSE) that gets incorporated into live cells
and gets diluted into daughter cells with every cell divi-
sion. The dilution in the intensity of the dye as estimated
by flow cytometry with respect to a "0" hour time point
gives an indication of the proliferation of the cells. Cells
were plated at a density of 1 × 105 in a 60 mm dish and
stained for 15 min using the fluorescent dye CFSE (Molec-
ular Probes). Cells were fixed in 70% alcohol just after
staining to have a 0 hour time point and after a period of
72 hours. Proliferation was then estimated using flow
cytometry using a FACSvantage™, Becton Dickinson
[20,21].
SIN1-1 and SNAP treatment and of mitochondrial damage
MCF12A parental cells were used for dose optimization of
the SIN1 and SNAP. An optimal dose was used for further
experiments. The parental and the transfected cells were
plated on a 60 mm dish to 70% confluency. Each of the
cell lines were treated with 4 mM 3-morpholinosydnon-
imine (SIN-1) and 2 mM S-nitroso-N-acetylpenicillamine
(SNAP), NO donors for a period of 1 hour after which the
medium was changed and cells were harvested after 0, 2,
4, 6 hour period intervals. DNA was extracted from these
cell lines and Cox I was PCR amplified and sequenced
using an automated sequencer (ABI PRISM) for mutation
analysis.
Uracil DNA Repair Assay
Uracil DNA repair assay was conducted as described by
Radany et al., [17]. Oligonucleotides used for the assay
were and T-34-mer 5'AGCTTGGCTGCAGGTXGACG-
GATCCC CGGGAATT-3' containing a uracil or thymine
residue at position 16 (X=U or T, respectively) and (A-34-
mer and G-34-mer) 5'-AATTCCCGGGGATCCGTCXAC-
CTGC AGCCAAGCT-3' containing an adenine or guanine
residue at position 19 (X = A or G, respectively). Twenty
picomoles of oligonucleotide substrates were labeled with
32P using T4 polynucleotide kinase. The labeled products
were precipitated and then resuspended in a lower vol-
ume of distilled water. These were directly used as single
stranded substrates in the enzyme assay. To prepare dou-
ble stranded substrates twenty picomoles of the labeled
products were annealed to 10 pmoles of the unlabelled
complementary or mismatch oligos by heating at 70°C
and slowly cooling it down to room temperature for an
hour. UDG assay was performed using 50 µg of mitochon-
drial extract in 1X UNG buffer (20 mM Tris-HCl pH8.0,1
mM EDTA,1 mM DTT) and 4 pmoles of labeled oligos.
The reaction was carried out at 30°C for 45 min. The assay
using commercially available Ugi (NEB) was performed
using similar conditions. Ten units of Ugi per reaction was
used. Apyrimidinic sites (AP-sites) generated by uracil
removal from DNA substrates were hydrolyzed by the
addition 0.1 N NaOH and incubating for 10 min at room
temperature and terminated using a formamide buffer
(80% formamide in 1XTBE) to generate single stranded
products. Half of the reaction was electrophoresed using a
15% acrylamide gel containing 8.3 M urea and 1X TBE
buffer. The gel was autoradiographed after electrophoresis
to visualize the bands.
Results
Generation of stable transfectants expressing UGI and 
UDG in the mitochondria
Previous studies have shown that uracil DNA glycolyase
can be inhibited by PBS2 phage protein UGI in a stoichi-
ometric fashion [17,18]. This protein has been used to
inactivate nuclear UDG by targeting it specifically to the
nucleus by attaching a nuclear localization signal [17]. We
have used the pCMV/myc/mito (Invitrogen) vector to tar-
get UGI protein in the mitochondria to inhibit UDG activ-
ity. Expression of UDG (UNG∆84), that retains the wild
type function of the enzyme, was also targeted to theMolecular Cancer 2004, 3:32 http://www.molecular-cancer.com/content/3/1/32
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mitochondria and was used as control. The pCMV/myc/
mito vector contains a mitochondrial localization signal
(MLS) of subunit VIII of human cytochrome c oxidase
that specifically targets a protein of choice to the mito-
chondria. Clones containing stable integration were iso-
lated and were confirmed by PCR upon transfection with
UGI gene and the UDG after G418 selection. To confirm
that the UGI gene was expressed in transfected cell lines
we did RT-PCR analysis (Figure 1). Our results show that
UGI was expressed (Figure 2). Western blot analysis on
extracts isolated from mitochondria using antibody
against UDG protein demonstrates that cells containing
UNG stable integration express higher level of UDG pro-
tein in the mitochondria (Figure 3, lane 3). It is important
to note that the UDG band was absent in cells expressing
UGI because UDG epitope was not available for binding
with antibody.
Expression of UDG and UGI in the mitochondria does not 
affect cell growth
It is possible that inhibition of UDG in the mitochondria
may affect cell growth. To determine if UGI expression in
the MCF12A cells resulted in a difference in cellular
growth, cell cycle analysis was conducted using flow
cytometry. The cell cycle distribution of parental MCF12A
cells, wild type UNG and UGI transfected cell line and the
cell line containing the control vector is shown in figure 4.
Interestingly, a very similar growth pattern was observed
between all the cell lines examined. We conclude that
expression of UGI in the mitochondria does not affect cell
growth.
Lack of mutations in COXI, COXII, and COXIII gene 
encoded by mtDNA
Our previous studies suggest that inactivation of UDG in
yeast Saccharomyces cerevisae leads to mutations in
PCR screening for stable integrants of pTZUGI in MCF12A  cells Figure 1
PCR screening for stable integrants of pTZUGI in MCF12A 
cells. PCR using pTZUGI primers were used to screen for 
stable integrants. Lane 1 is a positive control (pTZUgi plas-
mid DNA), lane 2, 3, 4, 5, 7, 8, 9 and 10 show the presence 
of stable integrants.
RT PCR to verify expression of Ugi gene transfected in  MCF12A cells using primers specic to the UGI gene Figure 2
RT PCR to verify expression of Ugi gene transfected in 
MCF12A cells using primers specic to the UGI gene: RT PCR 
products electrophoresed on a 1% agarose gel. Lane 1 shows 
RT PCR product from MCF12A cell line, lane 2 shows RT 
PCR product from MCF12A cells transfected with pCMV 
UNG, lane 3 shows RT PCR product from MCF12A trans-
fected with empty pCMV/myc/mito control vector, lane 4 
shows RT PCR product from MCF12A transfected with 
pCMV UGI vector.
Western blot analysis of mitochondrial UDG expression in  transfected cell lines Figure 3
Western blot analysis of mitochondrial UDG expression in 
transfected cell lines: Upper panel shows western blotting of 
mitochondrial extracts with UDG antibody the lower panel 
shows the same blot probed with Cox II antibody to assess 
for equal loading of the samples. Lane 1 is mitochondrial 
extract from parental MCF12A cells, lane 2 is mitochondrial 
extract from MCF12A cells transfected with empty pCMV/
myc/mito vector, lane 3 is mitochondrial extract from 
MCF12A cells transfected with pCMV UNG vector, lane 4 is 
mitochondrial extract from MCF12A cells transfected with 
pCMV UGI vector. A band of lower molecular weight was 
seen in some extracts.Molecular Cancer 2004, 3:32 http://www.molecular-cancer.com/content/3/1/32
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mtDNA [25]. We therefore asked whether UGI transfected
cells showed spontaneous increase in level of mutation in
mtDNA. We isolated mtDNA from cell expressing wild
type UNG, UGI and the control MCF12 A cells containing
vector. We amplified mtDNA encoding COXI, COXII and
COXIII by PCR. PCR fragments were sequenced. Sequenc-
ing revealed no differences in mtDNA sequence between
the cell lines expressing UGI, wild type UNG1 and the cell
line containing the vector (data not shown). We also
treated the transfected cell lines with two agents SIN1 and
SNAP. Both SIN1 and SNAP are known to deaminate
mtDNA [22]. The transfected cells were treated for one
hour with the agent and were harvested at different time
intervals to accumulate mutations. The DNA from these
cell lines was isolated and analyzed by sequencing for
mutations in the COXI, COX II and the COX III genes
encoded by the mtDNA. Our analysis showed no increase
in mutation in mtDNA in the treated cell lines (data not
shown). We conclude that UGI expression in the mito-
chondria does not lead to mutations in mtDNA.
FACS analysis of growth rate using fluorescent dye CFDA-SE Figure 4
FACS analysis of growth rate using fluorescent dye CFDA-SE: The first graph (green) in each panel shows fluorescent cells at 0 
hour time point and the second (black) shows a decrease in fluorescence at 72 hr after the cells proliferate. There is no differ-
ence in the growth rate between the parental cell line and the transfected one.Molecular Cancer 2004, 3:32 http://www.molecular-cancer.com/content/3/1/32
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Uracil repair is unaffected by inhibition of UDG in the 
mitochondria
It has been previously reported that the UGI protein when
targeted to the nucleus lowers the activity of the nuclear
UDG enzyme [16]. To analyze the effect of UGI expres-
sion on the mitochondrial UDG activity in the transfected
cell line, we carried out UDG activity measurements in
mitochondrial extracts with and without commercially
available UGI as a control. The commercially available
UGI was found to inhibit mitochondrial UDG. However,
constitutively expression of UGI in the mitochondria in
cell line transfected with UGI was not observed (Figure 5).
These results suggest two possibilities i) that an alternative
uracil glycosyalase activity is present in the mitochondria
and/or ii) mitochondrially expressed UGI is incapable of
inhibiting UDG present in the mitochondria. Since com-
mercially available UGI does inhibit mitochondrial UDG
activity, it is likely that alternative uracil glycosylase(s) are
present in the mitochondria. We conclude that uracil
repair is unaffected by inhibition of UDG in the
mitochondria.
Discussion
Cells are exposed to DNA damaging agents generated
both as a process of normal physiology as well through
extrinsic mutagens. Cells repair damage done to the DNA
by a variety of repair mechanisms each specific for the
type of DNA damage [23]. Many proteins involved in the
repair mechanism are conserved in prokaryotes and
eukaryotes. One of the repair mechanisms is the base exci-
sion repair pathway that repairs lesions of DNA that
involve base modification as well as damage by reactive
oxygen species. The enzymes involved in the base excision
repair pathway for the repair of the nuclear DNA are well
studied [23,24]. Base excision repair involves a DNA glyc-
osylase that cleaves the damaged base by hydrolysis of the
glycosidic bond, producing an abasic site. The abasic site
generated is then removed by AP endonuclease and the
gap is filled by DNA polymerase and then ligated by DNA
ligase [23,24]. The first enzyme involved in the base exci-
sion repair pathway differs depending upon the lesion
introduced in the DNA. Thus uracil DNA glycosylase is
specific for misincorporated uracil or deaminated cyto-
sine and would only act on these lesions [11-13]. Oxogua-
nine DNA glycosylase is specific for 8-oxoguanine and
other oxidative species, and 3-methyl adenine glycosylase
is specific for alkylated residues [10]. The mitochondrial
DNA is subjected to a greater risk of DNA damage due to
reactive oxygen species generated as a result of normal
physiology of this organelle. The proximity of the mito-
chondrial DNA to the electron transport chain makes it
more vulnerable to the DNA damaging effects of the
reactive oxygen species. Therefore, many of the base exci-
sion enzymes including UDG have isoforms that are tar-
geted to the mitochondria [9,10].
UDG's role in the nucleus is well established [17]. It is also
established that UGI, a PBS2 phage encoded protein when
expressed inhibits UDG activity in the nucleus [17,18]. In
this paper we investigated whether UDG is the major pro-
tein that plays an important role in repairing uracil resi-
dues in the mitochondria. In order to address this
question, we cloned UGI gene in frame with the
mitochondrial localization signal present in the pCMV/
myc/mito vector. We isolated stably transfected MCF12A
cell lines and measured uracil-DNA repair activity in the
mitochondria. We found no difference in DNA repair
activity of uracil in mitochondrial extracts. These results
were further substantiated by lack of spontaneous muta-
tions in mtDNA in the COXI, COXII and COXIII genes.
Similar results were obtained after treating the cells with
SIN1 and SNAP that deaminate DNA [22]. Cells express-
ing UGI also showed no difference in the growth rate
UDG activity in mitochondrial extracts of parental MCF12A  cells and transfected cell lines Figure 5
UDG activity in mitochondrial extracts of parental MCF12A 
cells and transfected cell lines: Lanes 1, 3, 5 and 7 show UDG 
activity in mitochondrial extracts from MCF12A parental cell 
line, cells transfected with pCMV UNG, cells transfected 
with pCMV UGI, cells transfected with pCMV/myc/mito con-
trol vector and commercially available UDG enzyme, that 
acted as a positive control, respectively. Lanes 2, 4, 6, 8 and 
10 shows an inhibition of UDG activity when commercially 
available Ugi was added in mitochondrial extracts from 
MCF12A parental cell line, cells transfected with pCMV 
UNG, cells transfected with pCMV UGI, cells transfected 
with pCMV/myc/mito control vector and commercially avail-
able UDG enzyme, that acted as a positive control, 
respectively.Molecular Cancer 2004, 3:32 http://www.molecular-cancer.com/content/3/1/32
Page 7 of 7
(page number not for citation purposes)
suggesting a lack of mitochondrial defect due to UGI inhi-
bition of mitochondrial UDG.
Our results of UGI expression in the mitochondria are dif-
ferent when compared with UGI expression in the
nucleus. A previous study has shown that expression of
UGI results in inhibition of uracil DNA repair in the
nucleus and subsequently mutation in the nuclear DNA
[17]. Our results are intriguing and hints to the presence
of alternative DNA repair proteins that may repair uracil
in mtDNA. Indeed, cells contain several classes of
enzymes that can remove uracil residues from DNA and
maintain genomic integrity [27]. These include the thym-
ine-DNA glycosylase (TDG), mismatch specific uracil-
DNA glycosylase (MUG) and the single-stranded mono-
functional uracil-DNA glycosyalse (SMUG1) [27,28]. It is
not clear whether any of these proteins are present in the
mitochondria and may function as a back up enzyme
when UDG is inactivated by UGI.
It is also possible that an extremely low level of mutant
mtDNA may be present in the cells expressing UGI in the
mitochondria and PCR technique used to identify mutant
copies among a heterogeneous population of mtDNA was
unable to detect mutant mtDNA molecules. It is also
conceivable that targeted UGI is present in a subset of
mitochondria and at any given time there is always
enough active UDG in vivo and in the extract from
untargeted mitochondria to carry out the uracil repair
activity in vitro. However, these possibilities are ruled out
because UGI expression did not result in lower level cyto-
chrome C oxidase activity (data not shown).
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